Indian Generics Makers Reap Benefits Of U.S. FDA Push For Approvals
This article was originally published in PharmAsia News
The decision by U.S. FDA to clear generic versions of Merck’s Singulair (montelukast) for treating asthma and allergies has been a boon to Indian drug makers such as Aurobindo and Glenmark.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
US FDA's Pediatric Experts, Not Review Division, Should Have Final Say On Pediatric Trials, Former Official Says
Former Associate Commissioner Janice Soreth says views of pediatric experts should take precedence over those of division directors regarding pediatric trials.